Savient Pharmaceuticals (SVNT) Inactive 10-Q2006 Q1 Quarterly report

Filed: 10 May 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Good

New words: ADAP, age, agency, aid, Analyst, binding, bioequivalence, biologic, bolstering, Catalyst, Citigroup, citrate, Code, competitor, compound, contractual, contraindicated, conventional, core, cumulative, Cytogen, Daily, dedicated, deleted, deletion, displacing, dividend, domestic, dosage, earmark, ES, ESPP, essential, examining, feet, forfeited, formulary, FPI, FSP, hyperuricemia, illustrated, inconsistent, ineffective, interruption, intradepartmental, intrinsic, involuntarily, largest, lesser, megace, midpoint, minimum, model, modified, monetization, multiplied, notification, older, orphan, outsourcing, overcharged, parallel, partner, partnering, Permacel, pool, pretax, priority, ratably, reconciliation, recruitment, refocused, removed, rental, repurchase, resource, selected, selection, shift, signature, simplified, software, source, specialist, spin, square, steady, structure, subleased, succeeded, switch, track, treasury, undergo, underperforming, unrecognized, unvested, upfront, validate, validating, wider, wire

Removed: account, acquired, analogue, appeal, arising, assembled, attorney, Barr, beginning, Berna, Biotech, budget, carried, categorizing, ceased, chance, collateral, combination, confirmation, conjunction, contracting, customer, depreciation, detail, devaluation, directed, Director, discussed, disease, draft, engineered, entitled, euro, exceeded, experimental, expiring, expressed, foregoing, fourth, Genentech, genetically, goodwill, indemnify, inflation, injection, instrument, insulin, investigate, Israeli, lagging, located, lost, measurable, neuropathic, neuropathy, nonrenewal, notably, objective, Oxandralone, panel, partial, penetration, peripheral, pertaining, pharmacology, pose, producing, protecting, reclassify, recording, recourse, reliably, reposition, retail, royalty, scheduled, Scientist, settled, Shekel, shipped, Squibb, sterling, suffered, synthetic, Taxation, unsatisfactory, upgrade, USA, vaccine, whichever, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SVNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Savient Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher G. Clement, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

6.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


7.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 10, 2006

	By:	Christopher G. Clement

		President and Chief Executive Officer